Cover Image

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

Show other versions (1)

For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apix...

Full description

Saved in:

Bibliographic Details
Main Author:	A. V. Rudakova (Author)
Format:	Book
Published:	Столичная издательская компания, 2015-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT
by: A. V. Rudakova
Published: (2015)

PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT
by: A. V. Rudakova
Published: (2015)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015)

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases
by: A. S. Kolbin, et al.
Published: (2023)

THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION
by: Rami N. Al-Ayyubi, et al.
Published: (2018)

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation
by: A. S. Kolbin, et al.
Published: (2023)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity
by: Izabela Kolasa, et al.
Published: (2023)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
by: Hallinen T, et al.
Published: (2021)

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
by: O. O. Shakhmatova
Published: (2020)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017)

APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE
by: O. O. Shakhmatova, et al.
Published: (2017)

Characteristics of patients with venous thromboembolism and atrial fibrillation in Venezuela
by: Abrahamson Page E, et al.
Published: (2011)

Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis
by: Ciuculete Denisa-Corina, et al.
Published: (2021)

Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation
by: Caroline Brais, et al.
Published: (2017)

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
by: Matthew J. Lawrence, et al.
Published: (2022)

Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation
by: L. N. Uddin, et al.
Published: (2019)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
by: Zalpour A, et al.
Published: (2014)

Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation
by: Simona Minardi, et al.
Published: (2024)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
by: Josep Comin Colet, et al.
Published: (2023)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020)

PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
by: A. V. Rudakova, et al.
Published: (2015)

PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
by: A. V. Rudakova, et al.
Published: (2015)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016)

A STRATEGY FOR MANAGING A PATIENT WITH ATRIAL FIBRILLATION TO REDUCE THE RISK OF THROMBOEMBOLIC COMPLICATIONS
by: L. I. Kudryavtseva, et al.
Published: (2019)

Characterization of atrial fibrillation and thromboembolic risk in patients of the Hospital León Cuervo Rubio
by: Eduardo Enrique Cecilia Paredes, et al.
Published: (2022)

CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
by: I. S. Yavelov
Published: (2015)

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
by: A. V. Rudakova, et al.
Published: (2021)

Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis
by: A. A. Sokolova, et al.
Published: (2022)

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer
by: E. P. Panchenko
Published: (2020)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
by: Yu-Sheng Lin, et al.
Published: (2021)